Age at biopsy (yrs) | 39.4 ± 8.2 |
---|---|
Ethnicity | |
White | 24 (40%) |
Other European | 24 (40%) |
Others | 12 (20%) |
Male | 54 (90%) |
Weight (kg) | 72.3 ± 10.1 |
> 75 kg | 24 (40%) |
Diabetes Mellitus | 3 (5%) |
Lipoatrophy | 5 (8%) |
Risk factors for HCV | |
IDU | 32 (53%) |
Blood transfusion | 3 (5%) |
Homosexual | 19 (32%) |
Heterosexual | 3 (5%) |
Tattoos/fisting | 3 (5%) |
Unknown | 1 (2%) |
Alcohol Abuse | 18 (30%) |
CD4+ (/mm3) | 450 (100–1200) |
HIV VL (copies/ml) | UD (UD-210,955) |
Antiretroviral therapy | |
None | 17 (28%) |
NRTI only | 10 (17%) |
HAART only | 22 (37%) |
Sequential therapy | 11 (18%) |
HCV VL (IU/ml)* | 869,299 (2716–14,975,540) |
HCV genotype 1* | 30/42 (71%) |
HCV disease duration (yrs) | 16.4 ± 8.0 |
Liver Biopsy** | |
Fibrosis stage | 2.8 ± 1.7 |
Fibrosis progression rate/yr | 0.21 ± 0.16 |
(FPR)* | |
Cirrhosis | 15 (25%) |
Necroinflammatory grade | 3.7 ± 1.7 |
Hepatic steatosis | 35 (58%) |